Reported 1 day ago
ProKidney Corp (NASDAQ:PROK) is positioning itself in the healthcare market with its promising cell therapy, Reparencel, as discussed at the Morgan Stanley Global Healthcare Conference. The company is halfway through enrolling patients in the ProAct One study, targeting chronic kidney disease patients, with top-line results expected by mid-2027. ProKidney maintains a healthy financial status with $295 million in cash and is enhancing its manufacturing capabilities in anticipation of demand. While the investment potential is noted, comparisons are made with AI stocks that may offer higher returns.
Source: YAHOO